Stockholder's Equity - Common Stock, Bridge Warrants (Details)														1 Months Ended	12 Months Ended			24 Months Ended
	Nov. 08, 2022 shares	Nov. 07, 2022 shares	Oct. 27, 2022	Oct. 26, 2022 shares	Aug. 04, 2022 $ / shares shares	Aug. 03, 2022 shares	Dec. 31, 2021 USD ($) shares	Nov. 09, 2021 $ / shares shares	Nov. 05, 2021 $ / shares	Nov. 02, 2021 USD ($) $ / shares shares	Nov. 19, 2020 $ / shares shares	May 22, 2020 $ / shares shares	May 18, 2020 USD ($) $ / shares shares	Aug. 31, 2022 $ / shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 shares	Dec. 31, 2022 USD ($) $ / shares shares	Mar. 04, 2021 $ / shares shares
Common Stock
Common shares outstanding	2,971,439	148,571,994					1,272,383	539,063		468,750			27,347		2,670,856	1,272,383		2,670,856
Shares issued to investors													83,733
Issuance of common stock and warrants, net of issuance costs (in shares)				36,166	931,667	36,196				426,500
Shares per warrant										1
Share issue price | $ / shares										$ 32.00
Warrants exercise price (in dollars per share) | $ / shares					$ 6.00
Number of common shares to issue on exercise of warrants															108,650			108,650
Number of warrants exercised							0
Warrant exercise price | $ / shares									$ 35.00
Reverse stock split ratio	0.02	0.02	0.02										0.0833
Number of fractional shares issued													0
Exercise of common warrants (in shares)																334,036		334,036
Granted															108,650			108,650
Weighted Average Remaining Contractual Term (Years) rollforward
Aggregate Intrinsic Value | $										$ 8,100,000
Maximum
Common Stock
Number of common shares to issue on exercise of warrants								539,063
Granted								539,063
Private Placement
Common Stock
Shares issued to investors													20,000,000
Aggregate net proceeds | $													$ 17,500,000
Over-Allotment option
Common Stock
Issuance of common stock and warrants, net of issuance costs (in shares)								70,313
Number of common shares to issue on exercise of warrants								70,313
Granted								70,313
BioPharmX
Common Stock
Fair value of common stock issued on acquisition | $													$ 8,400,000
Fair value per share of common stock issued on acquisition | $ / shares													$ 6.12
Merger Agreement
Common Stock
Reverse stock split ratio													0.0833
Patagonia
Common Stock
Common stock issued on acquisition													20
Conversion of common stock issued													12,591
TardiMed
Common Stock
Common stock issued on acquisition													180
Conversion of common stock issued													113,323
Number of common shares to issue on exercise of warrants															181,083			181,083
Outstanding, beginning of period
Granted															181,083			181,083
Exercised															(72,433)
Outstanding and exercisable, end of period															108,650			108,650
Weighted Average Exercise Price Rollforward
Weighted Average Exercise Price | $ / shares															$ 0.005
Weighted Average Price, Issued | $ / shares															0.005
Weighted Average Price, Exercised | $ / shares															$ 0.005
Weighted Average Remaining Contractual Term (Years) rollforward
Aggregate Intrinsic Value | $															$ 189,595			$ 189,595
Series A Warrants
Common Stock
Share issue price | $ / shares											$ 58.00				$ 139.77			$ 139.77
Warrants exercise price (in dollars per share) | $ / shares											$ 58.00				$ 58.00			$ 58.00
Number of common shares to issue on exercise of warrants											403,564				334,036			334,036
Exercise of common warrants (in shares)											403,564
Outstanding, beginning of period															334,036
Granted											403,564				334,036			334,036
Exercised															(167,695)
Outstanding and exercisable, end of period							334,036								334,036	334,036		334,036
Weighted Average Exercise Price Rollforward
Weighted Average Exercise Price | $ / shares															$ 58.00	$ 58.00
Weighted Average Remaining Contractual Term (Years) rollforward
Weighted average remaining contractual term ( in years)															2 years 8 months 12 days	3 years 4 months 24 days
Series B Warrants
Common Stock
Warrants exercise price (in dollars per share) | $ / shares											$ 0.05								$ 0.05
Number of common shares to issue on exercise of warrants																			455,336
Number of warrants exercised																	305,855
Exercise of common warrants (in shares)																149,353
Proceeds from issuance of warrants | $																$ 0
Granted																			455,336
Exercised																(149,481)
Bridge warrants
Common Stock
Warrants exercise price (in dollars per share) | $ / shares												$ 111.81
Amount of loan | $													$ 5,000,000
Number of common shares to issue on exercise of warrants												8,275
Warrant exercise price | $ / shares												$ 15.50		$ 1.00
Exercise of common warrants (in shares)															8,275	8,275
Outstanding, beginning of period															8,275
Granted												8,275
Outstanding and exercisable, end of period							8,275								8,275	8,275		8,275
Weighted Average Exercise Price Rollforward
Weighted Average Exercise Price | $ / shares															$ 1.00	$ 1.00
Weighted Average Remaining Contractual Term (Years) rollforward
Weighted average remaining contractual term ( in years)															2 years 4 months 24 days	3 years 4 months 24 days
Aggregate Intrinsic Value | $							$ 28,963								$ 6,206	$ 28,963		$ 6,206
November 2021
Common Stock
Number of warrants exercised															0	0
Warrant exercise price | $ / shares								$ 35.00
November 2021 | Maximum
Common Stock
Number of common shares to issue on exercise of warrants								539,063
Granted								539,063